Ford Motor Company vs Relay Therapeutics Inc. Common Stock — how do they compare? Ford Motor Company trades at $12.28 (market cap $48.85B), while Relay Therapeutics Inc. Common Stock trades at $17.5 (market cap $3.82B). The key difference: Ford Motor Company is far larger — about 12.8× Relay Therapeutics Inc. Common Stock's market cap, and Ford Motor Company pays a 4.9% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 104 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| F | RLAY | |
|---|---|---|
Market Cap | $48.85B | $3.82B |
Volume | 57,748,965 | 4,332,079 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $20.75 |
52-Week Low | $11.21 | $6.03 |
Typical Hold Time | 104 Days | 0 Days |
Enterprise Value | $180.81B | $2.93B |
Dividend Yield | 4.9% | — |
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.125, down 1.22% with a bearish technical outlook. The company reported mixed quarterly results, beating Q1 and Q2 2026 EPS estimates but missing Q4 2025. Recent news highlights a 6.6% Q3 sales decline due to model phase-outs and supplier issues affecting F-150 production. Cash flow improved in 2025 with $560M net inflow, but profitability remains challenged with negative net income margin of -3.93% and ROE of -18.31%.
Ford faces headwinds from declining sales and profitability challenges, though analyst consensus remains cautiously optimistic with a $15.90 price target. The stock offers value with low P/S (0.26) and P/E (11.21) ratios, but investors must weigh competitive pressures and execution risks against potential turnaround opportunities in hybrid vehicle adoption and commercial divisions.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →